文献速递咽喉与嗓音

一种新型体内 siRNA 递送至声带成纤维细胞的转染方式的初步研究

Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts.
PubMed 文献 · Laryngoscope · 2016-12-20

该体外研究比较了脂质体转染试剂与市售试剂递送 siRNA 抑制 Smad3 的效果,两种试剂在大鼠、兔和人声带成纤维细胞中均实现 60%~80% 的 mRNA 敲低(P < 0.05),脂质体表现良好且相当;给药剂量和次数显著影响抑制效果,血清和培养基类型不影响效率;脂质体值得进一步研究。

要点

  • 两种试剂在大鼠、兔和人声带成纤维细胞中均实现 60%~80% 的 Smad3 mRNA 敲低(P < 0.05)。
  • 给药剂量和给药次数显著影响基因抑制效果(P < 0.05),脂质体对剂量更敏感。
  • 血清和培养基类型均未改变转染效率。

核心结论

  • 脂质体在多种转染条件下有效敲低 Smad3 表达,这些初步数据令人鼓舞,脂质体值得进一步研究以实现临床用途。

研究设计与样本

  • 体外研究,比较脂质体寡聚物与市售转染试剂在不同物种声带成纤维细胞中的转染效率,靶基因为 Smad3。

主要发现

  • 两种试剂抑制 Smad3 mRNA 长达 96 小时,脂质体表现良好且相当。
  • 两种化合物在大鼠、兔和人声带成纤维细胞中均实现 60%~80% 的 mRNA 敲低(P < 0.05,相对于对照)。
  • 剂量和给药次数对基因抑制有显著作用(P < 0.05),脂质体的抑制更呈剂量敏感。
  • 在恒定 siRNA 浓度下,脂质体浓度增加五倍时观察到基因表达下降 50%。
  • 增加给药次数增强基因抑制,一次与四次给药之间下降约 45%;血清和培养基类型均未改变效率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An obstacle to clinical use of RNA-based gene suppression is instability and inefficiency of current delivery modalities. Nanoparticle delivery likely holds great promise, but the kinetics and transfection conditions must be optimized prior to in vivo utility. We investigated a RNA nanoparticle complex incorporating a lipitoid transfection reagent in comparison to a commercially available reagent. STUDY DESIGN: In vitro. METHODS: We investigated which variables influence transfection efficiency of lipitoid oligomers and a commercially available reagent across species, in vitro. These variables included duration, dose, and number of administrations, as well as serum and media conditions. The target gene was Smad3, a signaling protein in the transforming growth factor-β cascade implicated in fibroplasia in the vocal folds and other tissues. RESULTS: The two reagents suppressed Smad3 mRNA for up to 96 hours; lipitoid performed favorably and comparably. Both compounds yielded 60% to 80% mRNA knockdown in rat, rabbit, and human vocal fold fibroblasts (P < 0.05 relative to control). Dose and number of administrations played a significant role in gene suppression (P < 0.05). Suppression was more dose-sensitive with lipitoid. At a constant siRNA concentration, a 50% decrease in gene expression was observed in response to a five-fold increase in lipitoid concentration. Increased number of administrations enhanced gene suppression, ∼45% decrease between one and four administrations. Neither serum nor media type altered efficiency. CONCLUSION: Lipitoid effectively knocked down Smad3 expression across multiple transfection conditions. These preliminary data are encouraging, and lipitoid warrants further investigation with the goal of clinical utility. LEVEL OF EVIDENCE: NA. Laryngoscope, 127:E231-E237, 2017.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Kraja I, Bing R, Hiwatashi N, et al. Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts. Laryngoscope. 2016. PMID: 27996099. doi:10.1002/lary.26432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。